Age-related changes in the pharmacokinetics and pharmacodynamics of nifedipine
- PMID: 3358895
- PMCID: PMC1386353
- DOI: 10.1111/j.1365-2125.1988.tb03307.x
Age-related changes in the pharmacokinetics and pharmacodynamics of nifedipine
Abstract
1. The effects of age on the pharmacology of nifedipine were investigated in 11 young and six elderly normotensive volunteers. 2. Following 2.5 mg of nifedipine i.v. the plasma clearance of nifedipine was 348 +/- 83 (s.d.) ml min-1 in the elderly compared with 519 +/- 125 ml min-1 in the young (P less than 0.05) and the AUC in the elderly was significantly greater at 125 +/- 28 ng ml-1 h compared with 83.9 +/- 19 ng ml-1 h (P less than 0.05). The Vss was similar in both age groups. 3. Following 10 mg oral sustained release nifedipine the AUC was 281 +/- 64 ng ml-1 h in the elderly compared with 136 +/- 56 ng ml-1 h in the young (P less than 0.002) and Cmax in the elderly was significantly greater at 36.8 +/- 11.8 ng ml-1 compared with 22.3 +/- 5.8 ng ml-1 (P less than 0.05). The trend towards an increased bioavailability in elderly subjects (36%) was supported by a significantly lower nitropyridine metabolite/nifedipine ratio in the elderly. 4. Absorption rate limited kinetics of the sustained release formulation were indicated by the prolonged t1/2 compared with i.v. administration. In the elderly t1/2 (oral) was significantly greater than in the young (elderly 6.7 +/- 2.2 h, young 3.8 +/- 1.4 h, P less than 0.05). 5. Haemodynamic changes in the young were confined to a tachycardia following i.v. administration. In the elderly, supine BP fell significantly following both oral and i.v. nifedipine while the heart rate remained unchanged.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Bioavailability and pharmacokinetics of nifedipine administered by different routes in healthy volunteers.Arch Invest Med (Mex). 1989 Apr-Jun;20(2):129-35. Arch Invest Med (Mex). 1989. PMID: 2604495
-
Pharmacokinetics of a new extended-release nifedipine formulation following a single oral dose, in human volunteers.Drugs Exp Clin Res. 2005;31(3):115-21. Drugs Exp Clin Res. 2005. PMID: 16033250
-
Nifedipine: kinetics and dynamics in healthy subjects.Clin Pharmacol Ther. 1984 Jun;35(6):742-9. doi: 10.1038/clpt.1984.105. Clin Pharmacol Ther. 1984. PMID: 6734025
-
The pharmacokinetic profile of amlodipine.Am Heart J. 1989 Nov;118(5 Pt 2):1100-3. doi: 10.1016/0002-8703(89)90834-x. Am Heart J. 1989. PMID: 2530866 Review.
-
Nifedipine: variability in its kinetics and metabolism in man.Pharmacol Ther. 1989;44(3):445-54. doi: 10.1016/0163-7258(89)90010-7. Pharmacol Ther. 1989. PMID: 2519350 Review. No abstract available.
Cited by
-
Physiological changes due to age. Implications for cardiovascular drug therapy.Drugs Aging. 1991 Nov-Dec;1(6):467-76. doi: 10.2165/00002512-199101060-00006. Drugs Aging. 1991. PMID: 1794033 Review.
-
Clinical pharmacokinetics of nifedipine. Implications for the care of the elderly.Drugs Aging. 1997 Dec;11(6):470-9. doi: 10.2165/00002512-199711060-00006. Drugs Aging. 1997. PMID: 9413704 Review.
-
Drug-induced orthostatic hypotension in older patients.Drugs Aging. 1995 Mar;6(3):219-28. doi: 10.2165/00002512-199506030-00005. Drugs Aging. 1995. PMID: 7620234 Review.
-
Novel oral drug formulations. Their potential in modulating adverse effects.Drug Saf. 1994 Mar;10(3):233-66. doi: 10.2165/00002018-199410030-00005. Drug Saf. 1994. PMID: 8043223 Review.
-
Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications.Br J Clin Pharmacol. 2004 Jan;57(1):6-14. doi: 10.1046/j.1365-2125.2003.02007.x. Br J Clin Pharmacol. 2004. PMID: 14678335 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous